Skip to content

EEG Spectrogram-guided vs. Index-guided Anesthesia for Craniotomy

Comparisons Between Electroencephalographic Spectrogram-guided and Bispectral Index-guided Multimodal General Anesthesia During Craniotomy- a Randomized Controlled Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06244017
Enrollment
120
Registered
2024-02-06
Start date
2024-02-29
Completion date
2026-02-28
Last updated
2024-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Craniotomy

Brief summary

In this trial, investigators aimed to compared the clinical effects between the electroencephalographic (EEG) spetrogram-guided and processed EEG index-guided multimodal general anesthesia using the combination of propofol, dexmedetomidine, remifentnil and the scalp block in patients undergoing elective craniotomy.

Detailed description

The multimodal general anesthesia involved the administration of combinations of antinociceptive agents and hypnotics using electroencephalographic (EEG) based monitors to achieve a balanced state of anesthesia. Traditionally, the adjustment of general anesthesia drugs has been done using instruments like the Bispectral Index (BIS), which converts frontal lobe EEG signals into a numerical range of 0-100. This allows anesthesiologists to assess drug dosage and depth of anesthesia. However, numerical conversion may not accurately reflect individual variations and cannot precisely calculate drug concentrations in the case of multiple drug combinations. For instance, dexmedetomidine (DEX) is currently one of the most commonly used drugs in multimodal generagal anesthesia.Because each anesthetic produces distinct brain states that are readily visible in an EEG density spectral array (DSA) and can be easily interpreted by anesthesiologists, anesthetic titration based on an EEG DSA may provide additional information for anesthetic depth monitoring and may avoid the conventional 'one-index-fits-all' approach, which often ignores the influence of anesthetic drug combination. Theoretically, the anesthetic exposure in cases that involve the coadministration of dexmedetomidine can be more precise through the use of an EEG DSA than the use of BIS value. In accordant to this context, investigators have changed our institutional anesthetic propofol from BIS guidance to the DSA guidance and based on the retrospective analysis, investigators further observed the profound anesthetic-sparing effects and potential postoperative benefits of EEG DSA-guided anesthesia comparing to the BIS-guided anesthesia (doi: 10.4097/kja.23118). Therefore, further prospective randomized controlled is warranted to shape the real clinical benefits of DSA-guided multimodal general anesthesia.

Interventions

DEVICEEEG spectrogram

In the experimental group, the general anesthesia is guided by using the EEG spectrogram.

In the control group, the general anesthesia is guided by using the bispectral index

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients undergoing elective craniotomy

Exclusion criteria

* revision surgery * heart failure * liver cirrhosis \> Child B class * chronic obstructive pulmonary disease

Design outcomes

Primary

MeasureTime frameDescription
Intraoperative anesthetic dose4-6 hoursWe aim to compare the intraoperative propofol consumptions between the two study groups

Secondary

MeasureTime frameDescription
Postoperative neurological complication incidenceDuring the hospital stays; approximately 7-10 daysWe aim to compare the postoperative neurological complication incidence between the two study groups

Countries

Taiwan

Contacts

Primary ContactChun-Yu Wu
b001089018@tmu.edu.tw886976653376

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026